This registry is set up to collect real-world experience in the management of patients with
myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with
hypomethylating agents in Austria and potentially other participating countries. This
registry will collect data in a retrospective as well as in a prospective manner at various
sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a
routine clinical setting in patients with various comorbidities.